CPAP for Polycystic Ovary Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
In this study, the researchers are trying to learn more about the relationship between Polycystic Ovary Syndrome and Obstructive Sleep Apnea (OSA). Obstructive Sleep Apnea is a sleep-related breathing disorder that involves a decrease or complete stop in airflow. The purpose of this study is to find out why some people with obstructive sleep apnea have higher levels of insulin resistance, and the investigators will study the role of hypoxia (low levels of oxygen in the blood at night) in insulin resistance and see if insulin resistance improves during your treatment with CPAP.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently using oral contraceptives or being treated for asthma.
Is CPAP generally safe for humans?
CPAP (Continuous Positive Airway Pressure) is generally considered safe for humans, as it is commonly used to treat obstructive sleep apnea, a condition that affects breathing during sleep. Studies have shown that CPAP can improve health outcomes in people with sleep apnea, including those with conditions like polycystic ovary syndrome (PCOS).12345
How does CPAP treatment differ from other treatments for polycystic ovary syndrome (PCOS)?
CPAP (Continuous Positive Airway Pressure) treatment is unique for PCOS because it addresses sleep-disordered breathing, which is common in women with PCOS and can worsen metabolic issues. Unlike other treatments that focus directly on hormonal or metabolic symptoms, CPAP improves cardiometabolic function by treating obstructive sleep apnea, a condition often linked with PCOS.12678
What data supports the effectiveness of CPAP treatment for women with polycystic ovary syndrome (PCOS)?
Who Is on the Research Team?
Heather Huddleston, MD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for adults aged 18-40 with Polycystic Ovary Syndrome (PCOS) and moderate to severe Obstructive Sleep Apnea (OSA). Participants should have a BMI of 25-45, high fasting insulin levels, and meet specific PCOS criteria. Pregnant or breastfeeding individuals, those with untreated hypertension, HIV/hepatitis, asthma treatment, tobacco/alcohol use, prior OSA treatment or diabetes are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CPAP therapy or are placed in a delayed CPAP group for 12 weeks
Follow-up
Participants are monitored for changes in insulin resistance and other metabolic markers
What Are the Treatments Tested in This Trial?
Interventions
- Continuous Positive Airway Pressure Device (CPAP)
- Delayed Continuous Positive Airway Pressure Device (CPAP)
Continuous Positive Airway Pressure Device (CPAP) is already approved in United States, European Union, Canada, Japan for the following indications:
- Obstructive Sleep Apnea (OSA)
- Central Sleep Apnea (CSA)
- Obstructive Sleep Apnea (OSA)
- Central Sleep Apnea (CSA)
- Obstructive Sleep Apnea (OSA)
- Central Sleep Apnea (CSA)
- Obstructive Sleep Apnea (OSA)
- Central Sleep Apnea (CSA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor